Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
A. Grandi, M. Tomasi, S. Accordini, C. Bertelli, T. Vanzo, A. Gagliardi, E. Caproni, S. Tamburini, L. Fantappie, G. Di Lascio, Z. Bisoffi, C. Piubelli, M. T. Valenti, L. Dalle Carbonare, D. Zipeto, , G. Grandi
This study demonstrates that OMV-based SARS-CoV-2 vaccines induce neutralizing antibodies and protect mice from viral challenge.
bioRxiv · Jul 12, 2021 · PreprintImmunology